Translating Science into Clinical Success
Independent expertise in immuno-oncology, translational medicine and biomarker development

Independent expertise in immuno-oncology, translational medicine and biomarker development

Many development programmes generate large volumes of data. Far fewer generate true understanding.
I help teams connect disease biology, drug mechanism, patient heterogeneity and clinical outcomes into a coherent translational strategy.
My strength lies not in looking at individual biomarkers, but in recognising patterns, identifying missing links, and uncovering opportunities that may be overlooked when scientific disciplines operate in isolation.
By integrating evidence from pathology, immunology, flow cytometry, multi-omics and clinical data, I help organisations understand not only what is happening, but why it is happening. This approach enables the identification of mechanisms of response and resistance, patient stratification opportunities, and translational insights that support confident clinical decision-making.
I am known for asking unconventional questions and challenging assumptions that may otherwise go untested. Often, the most valuable insight is not found in the data itself, but in recognising what has not yet been explored.
The most valuable answers often come from the questions nobody thought to ask.
✅ Cell Therapies
✅ Microbial Therapies
✅ Targeted Protein Degraders
✅ Immune Checkpoint Inhibitors
✅ Combination Therapies
AML • MDS • Lymphoma • Multiple Myeloma
• Melanoma • NSCLC • NMIBC • HCC • PDAC • Breast Cancer • Ovarian Cancer